转移性激素敏感性前列腺癌的组织和血液来源基因组生物标志物:一项系统综述
该系统综述纳入11项研究共1682例转移性激素敏感性前列腺癌(mHSPC)患者,总结液体和/或组织活检中基因组改变的患病率及其临床意义。高瘤负荷疾病与TP53、DNA损伤修复和Wnt通路改变更频繁相关;新发mHSPC较复发疾病富集TP53和CDK12改变;AR、TP53、细胞周期信号和MYC改变与较差临床结局相关。作者呼吁这些潜在预测生物标志物需在生物标志物驱动的随机对照试验中验证后方可临床实施。
要点
- 高瘤负荷mHSPC与TP53、DNA损伤修复和Wnt通路改变更频繁相关。
- 新发mHSPC较复发疾病富集TP53和CDK12改变。
- AR、TP53、细胞周期信号和MYC改变与较差临床结局相关。
核心结论
- 多种基因组改变与mHSPC的不同预后和临床表型相关。
- 作者呼吁这些潜在预测生物标志物的新兴数据必须在生物标志物驱动的随机对照试验中验证后方可临床实施。
- 检测方法和报告的统一对齐对于确保快速可扩展性至关重要。
研究设计与样本
- 系统综述,系统检索PubMed和Web of Knowledge数据库至2021年1月。
- 使用Joanna Briggs Institute关键评价工具进行质量评估。
- 共纳入11项研究,涵盖1682例mHSPC患者。
主要发现
- 高瘤负荷疾病与TP53、DNA损伤修复和Wnt通路改变更频繁相关。
- 新发mHSPC患者的肿瘤较复发疾病富集TP53和CDK12改变。
- AR、TP53、细胞周期信号和MYC改变与较差的临床结局相关。
- 跨疾病状态的基因改变频率比较分析显示从局限性到去势抵抗性肿瘤相对增加,mHSPC中CTNNB1改变值得注意地富集(5%),值得进一步研究。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究受限于 eligible 研究间方法学和定义的可变性,包括测序方法、分析物(组织或液体)、改变调用阈值以及目标患者人群的差异,其中复发转移性疾病相对代表性不足。
- 原文结论指出这些潜在预测生物标志物的新兴数据必须在生物标志物驱动的随机对照试验中验证后方可临床实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Multiple studies have reported on the genomic characteristics of metastatic hormone-sensitive prostate cancer (mHSPC). The impact of these findings on prognostication, treatment selection, and clinical trial design remains unclear. OBJECTIVE: To summarise genomic alteration prevalences in liquid and/or tissue biopsies, infer their clinical implications, and compare genomic alteration frequencies across different disease states and clinical phenotypes. EVIDENCE ACQUISITION: The PubMed and Web of Knowledge databases were systematically searched up to January 2021. Quality assessment was performed using the Joanna Briggs Institute Critical Appraisal tools. EVIDENCE SYNTHESIS: In total, 11 studies encompassing 1682 mHSPC patients were included. High-volume disease was associated with more frequent alterations in TP53, DNA damage repair, and Wnt pathways. Tumours from patients with de novo mHSPC were enriched for alterations in TP53 and CDK12 compared with recurrent disease. Alterations in AR, TP53, cell cycle signalling, and MYC were associated with a poorer clinical outcome. A comparative analysis of gene alteration frequencies across disease states revealed a relative increase from localised to castration-resistant tumours, with noteworthy enrichment of CTNNB1 alterations in mHSPC (5%), which warrants further investigation. This study was limited by variability in methodology and definitions used among the eligible studies, including differences in sequencing methods, analytes (being either tissue or liquid), alteration calling thresholds, and target patient populations with a relative under-representation of recurrent metastatic disease. CONCLUSIONS: Several genomic alterations are associated with differential prognosis and clinical phenotypes in mHSPC. We urge that emerging data on these potential predictive biomarkers must be validated in biomarker-driven randomised controlled trials before any clinical implementation. Alignment of the assay methodology and reporting will be critical for ensuring rapid scalability. PATIENT SUMMARY: We reviewed current data on genomic alterations of metastatic hormone-sensitive prostate cancer, and summarised key genomic subtypes that associate with specific clinical phenotypes and treatment outcomes.
引用
- Van der Eecken K, Vanwelkenhuyzen J, Deek MP, et al. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review. Eur Urol Oncol. 2021. PMID: 34801437. doi:10.1016/j.euo.2021.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。